Recent Updates
Recently added Catalysts
NYXH Positive Sentiment

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

Tuesday, December 30, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Nyxoah SA will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will showcase their innovative Genio system for treating Obstructive Sleep Apnea (OSA). The company has achieved significant milestones, including FDA approval and CE mark for expanded indications. A live audio webcast will be available for interested investors.
Price reaction · baseline $4.75 (2025-12-29 close) · hit pre-market · clean, no other NYXH news in the window
day 0 close · peak
-2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nyxoah will present at a prestigious healthcare conference.
  • The company has received FDA approval for its Genio system.
  • Positive outcomes from recent studies highlight the efficacy of their treatment.

Full Press Release Details

Nyxoah to Present at the 44thAnnual J.P. Morgan Healthcare Conference
Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44thAnnual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.
A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website atinvestors.nyxoah.com.
About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visithttp://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Contact:

Frequently Asked Questions

When will Nyxoah present at the J.P. Morgan Conference?

Nyxoah will present on January 15, 2026, at 12:00 pm PT.

What is the Genio system used for?

The Genio system is a treatment for Obstructive Sleep Apnea through neuromodulation.

Has the Genio system received any approvals?

Yes, it received FDA approval in August 2025 and a CE mark in 2019.

Where can I watch Nyxoah's presentation live?

A live audio webcast will be available on Nyxoah's investor relations page.

ShareAdd on Google
Tags: NYXH Viatris Investor Conferences Healthcare Nyxoah Genio system Obstructive Sleep Apnea FDA approval J.P. Morgan Healthcare Conference
Last updated: Dec 30, 2025